Atrial-selective K<sup>+</sup>-channel blockade (mainly Kv1.5 and Kv4.3 channels conducting the sustained I<sub>Kur</sub> and transient I<sub>to</sub> outward currents) promises to suppress AF with a favorable benefit-to-harm ratio. The gene discussed is KCND3; the disease is atrial fibrillation.